pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

7,996 catalysts · 4,876 phase readout · 2,356 8k filing · 286 earnings · 275 pdufa · 166 phase 2 completion · 71 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 18 catalysts2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type
  • phase readout4,876
  • 8k filing2,356
  • earnings286
  • pdufa275
  • phase 2 completion166
  • phase 1 completion71
  • phase 2 initiation54
  • phase 1 initiation39
  • phase 1 2 completion33
  • phase 0 trial completion23
  • therapy area
    • Oncology139
    • Infectious Disease41
    • Cardiology37
    • Immunology32
    • Dermatology27
    • Pulmonology19
    • Women's Health16
    • Ophthalmology15
    • Pain12

    Week of Apr 20, 2026

    50
    ›Apr 25, 2026constraining patent expiry europe91d agoStemline Therapeutics Inc — SL-901 (Constraining Patent Expiry (Europe))SL-901

    Therapy area: Oncology, Undisclosed. Indication: Lung Cancer, Solid Tumor, Unspecified Rare Disease

    full page →SL-901 →source: globaldata
    ›Apr 25, 2026patent expiry91d agoStemline Therapeutics Inc — SL-901 (Constraining Patent Expiry (Japan))SL-901

    Therapy area: Oncology, Undisclosed. Indication: Lung Cancer, Solid Tumor, Unspecified Rare Disease

    full page →SL-901 →source: globaldata
    ›Apr 25, 2026phase 0 trial completion91d agoExegenesis Bio Inc — EXG-202 (Phase 0 Trial Completion)EXG-202

    Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Macular Degeneration, Wet (Neovascular / Exudative) Macular Degeneration

    full page →EXG-202 →source: globaldata
    ›Apr 25, 2026phase 1 completion91d agoChangchun Bcht Biotechnology Co Ltd — influenza (trivalent, split virion) vaccine (Phase I Trial Completion)influenza (trivalent, split virion) vaccine

    Therapy area: Infectious Disease. Indication: Unspecified Influenza Virus Infections

    full page →influenza (trivalent, split virion) vaccine →source: globaldata
    ›Apr 25, 2026phase 1 completion91d agoHenan Cancer Hospital — GH-2616 (Phase I Trial Completion)GH-2616

    Therapy area: Oncology. Indication: Lung Adenocarcinoma, Metastatic Colorectal Cancer, Metastatic Ovarian Cancer, Solid Tumor, Squamous Cell Carcinoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC), Uterine Cancer

    full page →GH-2616 →source: globaldata
    ›Apr 25, 2026phase 1 completion91d agoBristar Immunotech Biotechnology Co Ltd — YTS-109 (Phase I Trial Completion)YTS-109

    Therapy area: Hematological Disorders, Immunology. Indication: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Lupus Nephritis, Thrombocytopenia

    full page →YTS-109 →source: globaldata
    ›Apr 25, 2026phase 1 completion91d agoShenzhen Salubris Pharmaceuticals Co Ltd — (alisartan calcium + amlodipine besylate + sacubitril) (Phase I Trial Completion)(alisartan calcium + amlodipine besylate + sacubitril)

    Therapy area: Cardiovascular. Indication: Hypertension

    full page →(alisartan calcium + amlodipine besylate + sacubitril) →source: globaldata
    ›Apr 25, 2026phase 1 completion91d agoAin Shams University — Ketalar (Phase I Trial Completion)Ketalar

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →Ketalar →source: globaldata
    ›Apr 25, 2026phase 1 2 completion91d agoGeneral Hospital of the People's Liberation Army — cyclophosphamide (Phase I/II Trial Completion)cyclophosphamide

    Therapy area: Oncology. Indication: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Nodal Marginal Zone B-Cell Lymphoma, Non-Hodgkin Lymphoma, Primary Mediastinal B-Cell Lymphoma, Splenic Marginal Zone B-Cell Lymphoma

    full page →cyclophosphamide →source: globaldata
    ›Apr 25, 2026phase 1 2 completion91d agoShanghai YaKe Biotechnology Co Ltd — CD7 CAR-T Cells (Phase I/II Trial Completion)CD7 CAR-T Cells

    Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia

    full page →CD7 CAR-T Cells →source: globaldata
    ›Apr 25, 2026phase 2 completion91d agoAssiut University — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Other Diseases. Indication: Other Disease

    full page →dexamethasone →source: globaldata
    ›Apr 25, 2026phase 2 completion91d agoTianjin Medical University Cancer Institute and Hospital — fluorouracil (Phase II Trial Completion)Efudex

    Therapy area: Oncology. Indication: Bile Duct Cancer (Cholangiocarcinoma)

    full page →Efudex →source: globaldata
    ›Apr 25, 2026phase 2 completion91d agoHai Phong Medical University — Biolizin (Phase II Trial Completion)Biolizin

    Therapy area: Central Nervous System. Indication: Appetite (Eating) Disorders

    full page →Biolizin →source: globaldata
    ›Apr 25, 2026phase 2 completion91d agoKaraman Training and Research Hospital — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Central Nervous System, Musculoskeletal Disorders. Indication: Osteoarthritis, Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 25, 2026phase 2 completion91d agoChina Agricultural University — green tea (Phase II Trial Completion)green tea

    Therapy area: Metabolic Disorders. Indication: Obesity

    full page →green tea →source: globaldata
    ›Apr 25, 2026phase 2 completion91d agoMR Healthcare Pvt Ltd — Dyberine (Phase II Trial Completion)Dyberine

    Therapy area: Metabolic Disorders. Indication: Type 2 Diabetes

    full page →Dyberine →source: globaldata
    ›Apr 25, 2026phase 2 completion91d agoTehran University of Medical Sciences — FOLFOX [leucovorin + fluorouracil + oxaliplatin] (Phase II Trial Completion)FOLFOX [leucovorin + fluorouracil + oxaliplatin]

    Therapy area: Oncology. Indication: Rectal Cancer

    full page →FOLFOX [leucovorin + fluorouracil + oxaliplatin] →source: globaldata
    ›Apr 25, 2026phase 2 completion91d agoNational Institute of Siddha — undisclosed siddha medicine (Phase II Trial Completion)undisclosed siddha medicine

    Therapy area: Respiratory. Indication: Asthma

    full page →undisclosed siddha medicine →source: globaldata
    ›Apr 25, 2026phase 2 completion91d agoTamilnadu Government Dental College and Hospital — Gengigel (Phase II Trial Completion)Gengigel

    Therapy area: Infectious Disease. Indication: Dental Abscess

    full page →Gengigel →source: globaldata
    ›Apr 25, 2026phase 2 completion91d agoJawaharlal Nehru Medical College Ajmer — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System. Indication: Sedation

    full page →dexmedetomidine →source: globaldata
    ›Apr 25, 2026phase 2 completion91d agoSoochow University Hospital 1 — blinatumomab (Phase II Trial Completion)blinatumomab

    Therapy area: Oncology. Indication: B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

    full page →blinatumomab →source: globaldata
    ›Apr 25, 2026phase 2 completion91d agoNizam's Institute of Medical Sciences — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Central Nervous System, Genito Urinary System. Indication: Post-Operative Pain, Renal Stones/Calculi

    full page →dexamethasone →source: globaldata
    ›Apr 25, 2026phase 2 completion91d agoEmami Ltd — Himani fast relief gel (Phase II Trial Completion)Himani fast relief gel

    Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders. Indication: Inflammation, Myalgia (Muscle Pain), Unspecified Musculoskeletal Disorders

    full page →Himani fast relief gel →source: globaldata
    ›Apr 25, 2026phase 2 completion91d agoJawaharlal Nehru Medical College — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System, Other Diseases. Indication: Injury, Post-Operative Pain

    full page →dexmedetomidine →source: globaldata
    ›Apr 25, 2026phase 2 completion91d agoSeoul National University — onabotulinumtoxin A (Phase II Trial Completion)onabotulinumtoxin A

    Therapy area: Central Nervous System. Indication: Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy)

    full page →onabotulinumtoxin A →source: globaldata
    ›Apr 25, 2026phase 2 completion91d agoNational Taiwan University Hospital — levocarnitine (Phase II Trial Completion)Carnitor

    Therapy area: Gastrointestinal. Indication: Unspecified Gastrointestinal Disorders

    full page →Carnitor →source: globaldata
    ›Apr 25, 2026phase 2 completion91d agoFuzhou Second General Hospital — butorphanol (Phase II Trial Completion)butorphanol

    Therapy area: Musculoskeletal Disorders. Indication: Unspecified Musculoskeletal Disorders

    full page →butorphanol →source: globaldata
    ›Apr 25, 2026phase 2 initiation91d agoNovo Nordisk AS — zalfermin (Phase II Trial Initiation)zalfermin

    Therapy area: Gastrointestinal. Indication: Liver Failure (Hepatic Insufficiency)

    full page →zalfermin →source: globaldata
    ›Apr 25, 2026phase 2 initiation91d agoCoorg Instituite of Dental Sciences — chlorhexidine (Phase II Trial Initiation)chlorhexidine

    Therapy area: Mouth and Dental Disorders. Indication: Periodontitis

    full page →chlorhexidine →source: globaldata
    ›Apr 25, 2026phase 2 initiation91d agoAffiliated Renhe Hospital of China Three Gorges University — platelet rich plasma (Phase II Trial Initiation)platelet rich plasma

    Therapy area: Women's Health. Indication: Unspecified Gynecological Disorders

    full page →platelet rich plasma →source: globaldata
    ›Apr 25, 2026phase 2 initiation91d agoAffiliated Hospital of North Sichuan Medical College — Radioactive Iodine Therapy (Phase II Trial Initiation)Radioactive Iodine Therapy

    Therapy area: Oncology. Indication: Follicular Thyroid Cancer, Papillary Thyroid Cancer, Thyroid Cancer

    full page →Radioactive Iodine Therapy →source: globaldata
    ›Apr 25, 2026phase 2 initiation91d agoGSK plc — dostarlimab (Phase II Trial Initiation)dostarlimab

    Therapy area: Infectious Disease. Indication: Hepatitis B

    full page →dostarlimab →source: globaldata
    ›Apr 25, 2026phase 2 initiation91d agoKIMS Hospital — bifidobacterium (Phase II Trial Initiation)bifidobacterium

    Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

    full page →bifidobacterium →source: globaldata
    ›Apr 25, 2026phase 2 initiation91d agoShanghai Mental Health Center — undisclosed drug (Phase II Trial Initiation)undisclosed drug

    Therapy area: Central Nervous System. Indication: Anxiety Disorders

    full page →undisclosed drug →source: globaldata
    ›Apr 25, 2026phase 2 initiation91d agoCentenario Hospital Miguel Hidalgo — symbiotic (Phase II Trial Initiation)symbiotic

    Therapy area: Genito Urinary System. Indication: Chronic Kidney Disease (Chronic Renal Failure)

    full page →symbiotic →source: globaldata
    ›Apr 25, 2026phase 2 initiation91d agoGaziantep City Hospital — dexamethasone (Phase II Trial Initiation)dexamethasone

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →dexamethasone →source: globaldata
    ›Apr 25, 2026phase 2 initiation91d agoShanghai Henlius Biotech Inc — HLX-43 (Phase II Trial Initiation)HLX-43

    Therapy area: Oncology. Indication: Breast Cancer, Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC)

    full page →HLX-43 →source: globaldata
    ›Apr 25, 2026phase 2 initiation91d agoJazz Pharmaceuticals Plc — durvalumab (Phase II Trial Initiation)durvalumab

    Therapy area: Oncology. Indication: Small-Cell Lung Cancer

    full page →durvalumab →source: globaldata
    ›Apr 25, 2026phase 2 initiation91d agoGlenmark Pharmaceuticals Ltd — (clascoterone + latanoprost) (Phase II Trial Initiation)(clascoterone + latanoprost)

    Therapy area: Dermatology. Indication: Androgenic Alopecia

    full page →(clascoterone + latanoprost) →source: globaldata
    ›Apr 25, 2026phase 2 initiation91d agoNovartis AG — asciminib hydrochloride (Phase II Trial Initiation)asciminib hydrochloride

    Therapy area: Oncology. Indication: Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

    full page →asciminib hydrochloride →source: globaldata
    ›Apr 25, 2026phase 3 completion91d agoMashhad University of Medical Sciences — acetazolamide (Phase III Trial Completion)ACETAZOLAMIDE

    Therapy area: Central Nervous System. Indication: Epilepsy

    full page →ACETAZOLAMIDE →source: globaldata
    ›Apr 25, 2026phase 3 completion91d agoAin Shams University — lidocaine (Phase III Trial Completion)LIDOCAINE

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →LIDOCAINE →source: globaldata
    ›Apr 25, 2026phase 3 initiation91d agoOTCPharm — OTC-BSR-0125 (Phase III Trial Initiation)OTC-BSR-0125

    Therapy area: Gastrointestinal. Indication: Anal Fissure, Hemorrhoids

    full page →OTC-BSR-0125 →source: globaldata
    ›Apr 25, 2026phase 3 initiation91d agoSwami Dayanand Hospital — levobupivacaine (Phase III Trial Initiation)levobupivacaine

    Therapy area: Central Nervous System, Gastrointestinal. Indication: Inguinal Hernia, Post-Operative Pain

    full page →levobupivacaine →source: globaldata
    ›Apr 25, 2026phase 3 initiation91d agoDr. Reddy's Laboratories Ltd — olokizumab (Phase III Trial Initiation)olokizumab

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →olokizumab →source: globaldata
    ›Apr 25, 2026phase iii iv trial completion91d agoParul Institute of Homoeopathy And Research — ferrum phosphoricum (Phase III/IV Trial Completion)ferrum phosphoricum

    Therapy area: Hematological Disorders. Indication: Iron Deficiency Anemia

    full page →ferrum phosphoricum →source: globaldata
    ›Apr 25, 2026phase iv trial initiation91d agoChristian Medical College Vellore — ketorolac (Phase IV Trial Initiation)ketorolac

    Therapy area: Central Nervous System, Genito Urinary System. Indication: Pain, Renal Colic, Renal Stones/Calculi

    full page →ketorolac →source: globaldata
    ›Apr 25, 2026phase iv trial initiation91d agoIstinye University — undisclosed general anesthesia (Phase IV Trial Initiation)undisclosed general anesthesia

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →undisclosed general anesthesia →source: globaldata
    ›Apr 26, 2026constraining patent expiry europe90d agoBlue Blood Biotech Corp — BB-101 (Constraining Patent Expiry (Europe))BB-101

    Therapy area: Dermatology. Indication: Diabetic Foot Ulcers

    full page →BB-101 →source: globaldata
    ›Apr 26, 2026patent expiry90d agoBlue Blood Biotech Corp — BB-101 (Constraining Patent Expiry (Japan))BB-101

    Therapy area: Dermatology. Indication: Diabetic Foot Ulcers

    full page →BB-101 →source: globaldata
    ← prev
    page 1 of 160
    next →
    $JAZZ254.74-0.05%
    $GSK51.28+1.07%
    $NVS156.14+2.00%